PriceTargets.com logo

Avenue Therapeutics - ATXI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.72 As of 07/26/2024 01:00 AM ET
▼ -0.15 (-5.23%)

This chart shows the closing price for ATXI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avenue Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATXI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Avenue Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.72.

This chart shows the closing price for ATXI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Avenue Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2023Maxim GroupInitiated CoverageBuyLow
4/3/2023AegisInitiated CoverageBuy$2,400.00Low
12/18/2020HC WainwrightReiterated RatingHold$6,750.00High
10/12/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
5/12/2020HC WainwrightBoost TargetBuy$13,500.00 ➝ $14,625.00Medium
2/13/2020HC WainwrightReiterated RatingBuy$13,500.00Medium
(Data available from 7/26/2019 forward)

News Sentiment Rating

-0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/28/2024
  • 4 very positive mentions
  • 37 positive mentions
  • 9 negative mentions
  • 7 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 45 positive mentions
  • 21 negative mentions
  • 12 very negative mentions
Mentions as of
3/28/2024
  • 1 very positive mentions
  • 36 positive mentions
  • 14 negative mentions
  • 6 very negative mentions
Mentions as of
4/27/2024
  • 5 very positive mentions
  • 25 positive mentions
  • 10 negative mentions
  • 2 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
Mentions as of
6/26/2024
  • 1 very positive mentions
  • 24 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 1 very positive mentions
  • 24 positive mentions
  • 7 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Avenue Therapeutics logo
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Read More

Today's Range

Now: $2.72
Low: $2.60
High: $3.06

50 Day Range

MA: $3.51
Low: $2.72
High: $3.81

52 Week Range

Now: $2.72
Low: $2.60
High: $85.50

Volume

133,729 shs

Average Volume

70,260 shs

Market Capitalization

$2.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Avenue Therapeutics?

The following sell-side analysts have issued research reports on Avenue Therapeutics in the last twelve months: Maxim Group.
View the latest analyst ratings for ATXI.

What is the current price target for Avenue Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Avenue Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Avenue Therapeutics in the next year.
View the latest price targets for ATXI.

What is the current consensus analyst rating for Avenue Therapeutics?

Avenue Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATXI will outperform the market and that investors should add to their positions of Avenue Therapeutics.
View the latest ratings for ATXI.

What other companies compete with Avenue Therapeutics?

Other companies that are similar to Avenue Therapeutics include Trevena, Chemomab Therapeutics, Kiora Pharmaceuticals, BriaCell Therapeutics and Universe Pharmaceuticals. Learn More about companies similar to Avenue Therapeutics.

How do I contact Avenue Therapeutics' investor relations team?

Avenue Therapeutics' physical mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company's listed phone number is (781) 652-4500 and its investor relations email address is [email protected]. The official website for Avenue Therapeutics is www.avenuetx.com. Learn More about contacing Avenue Therapeutics investor relations.